FDA's RP1 Rejection Signals Regulatory Transformation
Interesting take. What do you see happening after Prasad leaves?
I think Remplimune will seek FDA guidance and hopefully a new lease of life with proper guidance back to early approval.
Well done and very logical.
How best can we raise this issue to the decision makers that can make a difference in this stifling of quantum leaps in treatment?
Thank you.
Interesting take. What do you see happening after Prasad leaves?
I think Remplimune will seek FDA guidance and hopefully a new lease of life with proper guidance back to early approval.
Well done and very logical.
How best can we raise this issue to the decision makers that can make a difference in this stifling of quantum leaps in treatment?
Thank you.